Skip to main
  1. Stocks
  2. Caribou Biosciences
  3. Forecast
CRBU

Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences (CRBU) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Caribou Biosciences is attractive fundamentally because its chRDNA gene-editing platform is differentiated, designed to improve specificity and reduce off-target effects, while also avoiding some of the IP complexities that cloud other CRISPR approaches. The company’s focus on validated oncology targets like CD19 and BCMA, combined with its allogeneic CAR-T programs already in the clinic, gives the story a relatively high probability of success and a near-term catalyst with data expected in 2H25. Financially, the stock trading close to cash and the $25 million Pfizer equity investment strengthen the downside case while highlighting external validation of the platform and its potential to improve T-cell persistence and durability.

Bears say

Caribou Biosciences is viewed negatively because it is effectively winding down its core business, with management planning to discontinue further development of both allogeneic CAR-T programs, vispa-cel and CB-011, after citing a challenging financing environment and lack of capital availability. The company’s decision to explore strategic alternatives, including a merger or acquisition, signals that internal execution alone is no longer sufficient, while workforce and cost reductions expected to be completed by 4Q26 underscore the severity of the reset. Although it reported $113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, the downside case assumes 0% probability of success across NHL, MM, AML, and the platform, leaving very limited fundamental support.

Caribou Biosciences (CRBU) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction

Get the latest Caribou Biosciences (CRBU) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Caribou Biosciences (CRBU)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Caribou Biosciences (CRBU) Forecast

Analysts have given Caribou Biosciences (CRBU) a Buy based on their latest research and market trends.

According to 6 analysts, Caribou Biosciences (CRBU) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Caribou Biosciences (CRBU)


Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction

Get the latest Caribou Biosciences (CRBU) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Caribou Biosciences (CRBU)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CRBU stock data and trends